Adjunctive Triple Chronotherapy in the Treatment of Adolescent Major Depressive Disorder: A Randomized Controlled Pilot Trial
Journal of Child and Adolescent Psychopharmacology · 2026
DOI: 10.1177/10445463251389899 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Child and Adolescent Psychopharmacology, 2026. Verfasst von Mariela Herrera und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Billings Clinic, Billings, Montana, USA. Hauptthemen laut MEDLINE: Major Depressive Disorder, Chronotherapy, Phototherapy, Antidepressive Agents. Die Arbeit nennt 33 Literaturangaben.
Abstract (Originalsprache)
Introduction
This randomized controlled pilot trial examined whether adjunctive triple chronotherapy (TCT) in adolescents hospitalized with major depressive disorder (MDD) was (1) feasible, and (2) suggested to be more effective in managing depression and accompanying symptoms at 60 days postdischarge, compared to adolescents with depression who received treatment-as-usual (TAU).
Methods
TCT participants underwent sleep deprivation for up to 36 hours, sleep phase advancement for four days, and daily exposure to light therapy. Both arms received medication management and group therapy during the inpatient stay. Outpatient visits occurred on Days 7/10, 30, and 60. Outcomes included depression, anxiety, insomnia, self-harm, suicidality, and quality of life.
Results
Sixty-four adolescents were enrolled, 32 into TCT, 32 into TAU. The mean age was 15 years, the majority were female, Caucasian, and non-Hispanic/non-Latino. Compared to baseline, both TCT and TAU participants showed a significantly lower Patient Health Questionnaire-Adolescent (PHQ-A) score by Day 4 (TCT: N = 31, X ¯ =20.4 ± 3.54 vs. N = 17, X ¯ =9.12 ± 6.98, p < 0.001; TAU: N = 32; X ¯ =20.1 ± 3.99 vs. N = 10; X ¯ =8.6 ± 5.93, p < 0.001) and by Day 60 (TCT: N = 11, X ¯ =7.45 ± 5.22, p < 0.001; TAU: N = 14, X ¯ =13.36 ± 7.25, p < 0.001). For between-group differences, TCT participants reported significantly lower PHQ-A scores at Day 60 compared to TAU participants ( N = 11, X ¯ =7.45 ± 5.22 vs. N = 14, X ¯ =13.36 ± 7.25, p = 0.03). Anxiety and insomnia were significantly lower at treatment end in the TCT arm ( N = 11, X ¯ =1.91 ± 1.97 vs. N = 14; X ¯ =4.64 ± 2.79, p = 0.009) and ( N = 11, X ¯ =6.55 ± 6.64 vs. N = 14; X ¯ =12.21 ± 6.76, p = 0.05), respectively. Retention was a challenge; approximately 2/3 of the sample dropped out by study end.
Conclusions
TCT is a potentially effective adjunctive treatment for MDD in adolescents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Billings Clinic, Billings, Montana, USA.
- Beginner's Mind Mental Health Services, Billings, Montana, USA.
- Collaborative Science & Innovation, Billings Clinic, Billings, Montana, USA.
- Department of Mathematics & Statistics, Murray State University, Murray, Kentucky, USA.
- City of Hope National Medical Center, Duarte, California, USA.
Zitieren
APA
Herrera, M., Hurd, D., Riemann, L. A., Mullowney, Y., Pathak, M., Swift, K., Fairbanks, C., Winsky, J., & Brant, J. M. (2026). Adjunctive Triple Chronotherapy in the Treatment of Adolescent Major Depressive Disorder: A Randomized Controlled Pilot Trial. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1177/10445463251389899
Vancouver
Herrera M, Hurd D, Riemann LA, Mullowney Y, Pathak M, Swift K, et al. Adjunctive Triple Chronotherapy in the Treatment of Adolescent Major Depressive Disorder: A Randomized Controlled Pilot Trial. Journal of Child and Adolescent Psychopharmacology. 2026. doi:10.1177/10445463251389899
BibTeX
@article{Herrera2026,
author = {Herrera, Mariela and Hurd, Diane and Riemann, Laurie A and Mullowney, Yvonne and Pathak, Manoj and Swift, Kristen and Fairbanks, Cara and Winsky, Jennifer and Brant, Jeannine M},
title = {Adjunctive Triple Chronotherapy in the Treatment of Adolescent Major Depressive Disorder: A Randomized Controlled Pilot Trial},
journal = {Journal of Child and Adolescent Psychopharmacology},
year = {2026},
doi = {10.1177/10445463251389899}
}
EUVIMED